AD Ports Group and Hayat Biotech have signed a Memorandum of Understanding (MoU) to support Hayat Biotech’s global logistics and distribution efforts through AD Ports Group’s advanced pharma logistics network, which includes its cold and ultra-cold pharma hub based in KIZAD.
Specifically, the partnership will help facilitate Hayat Biotech’s efforts to set up manufacturing centers around the globe and provide logistics solutions to serve its international markets.
The initial element of the agreement encapsulates the shipping of strategic construction supplies, including containers, machinery, raw materials, and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities.
Once completed, the facilities will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced COVID-19 vaccine in the UAE and the Arab world. As part of the collaboration, the distribution will be handled by the HOPE Consortium, an Abu Dhabi-led partnership that operates one of the largest and most complete end-to-end pharma supply chains on the market today.
Captain Mohamed Juma Al Shamsi Group CEO & MD AD Ports Group
“As a nation, the UAE continues to take significant steps towards enabling global access to pharmaceutical products and supplies. Thanks to our partnership with Hayat Biotech, we are cementing the pivotal role that AD Ports Group and the HOPE Consortium are playing in supporting our healthcare industry’s efforts to serve communities and markets all around the world. AD Ports Group continues to deliver on our leadership’s vision of establishing Abu Dhabi as a global life sciences hub, and our partnership with Hayat Biotech is another important milestone along our journey towards achieving that goal.”
Mr. Naser Al Yammahi, Deputy CEO of Hayat Biotech, said that “The world is facing fundamental challenges that are affecting our wellbeing, health, and quality of life, therefore, we made it our responsibility to deliver innovative biotechnological capabilities around the globe. Thanks to the partnership with AD Ports Group, we are looking to further expand our distribution network to deliver necessary biopharmaceutical products to improve the health of our nation and across the globe.”
As a UAE-based company, Hayat Biotech, a Joint Venture between Abu Dhabi’s G42 and Sinopharm CNBG, focuses on the development of life sciences through advanced clinical trials, medical R&D, distribution of new pharmaceutical products, and vaccines. The company began locally producing the Hayat-Vax vaccine in March 2021, which has been distributed worldwide, in part, by the HOPE Consortium partnership.
